Vol.55 No.S-1 October 2007
In vitro antibacterial activity of garenoxacin
Jpn. J. Chemother. 55 (S-1): 1-20, 2007
In vivo antibacterial activity of garenoxacin
Jpn. J. Chemother. 55 (S-1): 21-27, 2007
Single-dose toxicity studies of garenoxacin in mice, rats, and dogs
Jpn. J. Chemother. 55 (S-1): 28-33, 2007
Three-month repeated oral dose toxicity study of garenoxacin in rats
Jpn. J. Chemother. 55 (S-1): 34-41, 2007
Three-month repeated oral dose toxicity study of garenoxacin in cynomolgus monkeys
Jpn. J. Chemother. 55 (S-1): 42-53, 2007
Genotoxicity study of garenoxacin
Jpn. J. Chemother. 55 (S-1): 54-61, 2007
Reproductive and developmental toxicity studies of garenoxacin
Jpn. J. Chemother. 55 (S-1): 62-74, 2007
Phototoxicity study of garenoxacin in guinea pigs
Jpn. J. Chemother. 55 (S-1): 75-77, 2007
Pharmacokinetics of garenoxacin in laboratory animal species
Jpn. J. Chemother. 55 (S-1): 78-86, 2007
In vitro metabolism and the effect on human cytochrome P450s of garenoxacin
Jpn. J. Chemother. 55 (S-1): 87-94, 2007
Phase 1 clinical studies of oral garenoxacin in healthy Japanese adult subjects
Jpn. J. Chemother. 55 (S-1): 95-115, 2007
Clinical phase II study of garenoxacin in patients with respiratory tract infections -openlabel, multicenter, noncomparative-
Jpn. J. Chemother. 55 (S-1): 116-126, 2007
Clinical phase III comparative study on garenoxacin versus levofloxacin in patients with bacterial pneumonia
Jpn. J. Chemother. 55 (S-1): 127-143, 2007
Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases
Jpn. J. Chemother. 55 (S-1): 144-161, 2007
Penetration into sputum study of garenoxacin in patients with secondary infection of chronic respiratory disease
Jpn. J. Chemother. 55 (S-1): 162-168, 2007
Clinical phase III study of oral garenoxacin in patients with community-acquired acute respiratory infection
Jpn. J. Chemother. 55 (S-1): 169-184, 2007
Clinical phase III open-labeled study of oral garenoxacin in patients with respiratory tract infection by penicillin-resistant Streptococcus pneumoniae
Jpn. J. Chemother. 55 (S-1): 185-193, 2007
Clinical phase III open-label study of oral Garenoxacin in patients with otorhinolaryngological infection
Jpn. J. Chemother. 55 (S-1): 194-205, 2007
Concomitant administration study of garenoxacin and theophylline
Jpn. J. Chemother. 55 (S-1): 206-213, 2007
Relationship between oral administration of garenoxacin and QT interval
Jpn. J. Chemother. 55 (S-1): 214-221, 2007
Clinical response of garenoxacin against respiratory tract infection and otorhinolaryngological infection caused by multidrug-resistant Streptococcus pneumoniae
Jpn. J. Chemother. 55 (S-1): 222-230, 2007